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in 2012, endorsed its use for prevention of postpartum hemorrhage by
community healthworkers. However, it stopped short of recommending
it for advanced distribution to women, citing insufﬁcient evidence [3,9].
Since then, several studies have been conducted that provide convincing1. Introduction
Postpartum hemorrhage is the leading cause of maternal mortality
in low-income countries, accounting for more than 30% of maternal
deaths [1,2], and it is arguably themost preventable [3]. The risk of hem-
orrhage at birth is highest forwomenwhodeliver at homebecause they
do not beneﬁt from the support of skilled birth attendants and are
less likely to receive care and medications that prevent postpartum
hemorrhage. One promising approach to the prevention of postpartum
hemorrhage among these women is to provide misoprostol—an inex-
pensive pill that, when taken immediately after delivery, can reduce
the risk of postpartum hemorrhage by 24%–47% [4–7]. Because
misoprostol is easy to administer, heat stable with a long shelf life,
and inexpensive, it is an invaluable tool for both the prevention and
treatment of postpartum hemorrhage in under-resourced healthcare
systems [8]. It is also an important alternative to oxytocin—the recom-
mended uterotonic—in cases of stockouts or when potency has been
compromised by heat exposure.e previously published by the
alth Grantmaking in Ethiopia,
ublished by permission of the
98607,USA.Tel.:+13608330925.
valuation took place.
logy and Obstetrics. Published by
.evidence of the safety of advance distribution of misoprostol [10–13],
and it is anticipated that WHO will soon update its endorsement to
include advance provision of misoprostol. The evidence, combined
with the global focus on improving maternal health indicators to meet
the 2015MillenniumDevelopment Goals, sparked the interest of nation-
al governments and international funders in the scaling up of cost-
effective community-based distribution models [7,14].
In Ethiopia, Ghana, and Nigeria, the incidence of maternal mortality
due to postpartum hemorrhage is high, and many women still deliver
at home (Table 1). Recognizing the potential that misoprostol could
have for reducing maternal mortality in these countries, in 2004, the
MacArthur Foundation began investing in a package of grants designed
to explore ways to use misoprostol at the community level to prevent
postpartum hemorrhage. The focus of the grants was on achieving
sustainable solutions that could be scaled up nationwide. In 2014, the
Foundation commissioned the Public Health Institute to do a process
evaluation of these grants and document the models and approaches
used to scale up the respectivemodels in the three countries. In the pres-
ent report, themodels and approaches used in the three countries are de-
scribed, evaluated as to their potential for achieving scale-up in the
future, and compared between countries, with a highlight on the lessons
learned to inform other governments committed to reducing postpartum
hemorrhage and meeting the new Sustainable Development Goals.2. Methods
Between June and November 2014, the evaluation team reviewed
grantee reports, proposals, and the literature; interviewed key infor-
mants and global, national, and local stakeholders; conducted focus
group discussions with local stakeholders; and made observationsElsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
Table 1
Key indicators relating to maternal health in project countries.a
Indicator Ethiopia Ghana Nigeria
Maternal mortality ratio, deaths per 100 000 live birthsb,c,d 420 (240–720) 380 (210–720) 560 (300–1000)
Annual number of maternal deathsb 13 000 3100 40 000
Prenatal care (≥1 visit), % 42.5e 96.4f 66.2g
Home delivery, %d 85h 33f 55g
a Values are given as mean (range), number, or percentage.
b Source: World Health Organization, United Nations Children’s Fund, United Nations Population Fund, The World Bank, United Nations [15].
c The mean estimated maternal mortality ratio in high-income regions is 16 (range 12–23) [15].
d These are national averages but in all three countries, the rates are higher in rural areas.
e Source: United Nations Children’s Fund [16].
f Source: United Nations Children’s Fund [17].
g Source: United Nations Children’s Fund [18].
h Source: Central Statistical Agency [19].
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tional Review Board (IRB) and each country’s review board or ethics
committee approved the focus group research protocols before the re-
search was undertaken (IRB # I14-012). Overall, 100 key informants
and 216 focus group participants contributed information to the evalu-
ations. A case study report was produced for each country and the ﬁnd-
ings of the three reports were synthesized.
3. Models and ﬁndings
3.1. Overview
Several models of community-based distribution of misoprostol
have emerged since 2004, including advanced distribution to women
through prenatal care visits or by a community agent, administration
to women at birth by community health workers or traditional birth at-
tendants, and hybridmodels that include both advanced distribution di-
rectly to women before birth and distribution at birth by skilled birth
attendants. The models and approaches supported by the MacArthur
Foundation in Ethiopia, Ghana, and Nigeria varied across the countries.
Although they had numerous elements in common, they also differed
in signiﬁcant ways (Table 2).
3.2. Ethiopia: Distribution at home birth by layworkers to expand the reach
of the health system
The Ethiopia project, funded in 2008, focused on the use of lay
workers to expand and support the government’s health extension pro-
gram by bringing misoprostol to women giving birth at home. YouthTable 2
Comparison of the community-based distribution models.
Aspects of the models Ethiopia Ghana
Approach used Distribution at home birth: lay youth mentors
(from Ministry of Youth and Sports) and CHEWs
educate women during pregnancy, encourage
facility delivery, and bring misoprostol to
home births
Advance dis
pregnant w
delivery; wo
midwife at 7
Timing of drug availability At home birth In advance o
facility)
Organizational structures
involved
Regional Health Bureau and Ministry of Youth
and Sports
Ghana Heal
Successes Increase in uterotonic coverage of home births Increase in
Increased fa
Challenges Mentors and CHEWs could not always reach
women with misoprostol during home births;
Program viewed as inconsistent with
government emphasis on facility delivery;
Concern about misuse
Limited res
other rural
Concern ab
Abbreviations: CHEW, community health extension worker; TBA, traditional birth attendant.mentors, hired as part of a collaboration between the Population Coun-
cil and theMinistry of Youth and Sports (now theWomen, Children, and
Youth Bureau), worked closely with community health extension
workers from the Amhara Regional Health Bureau to expand outreach
into rural communities where great distances and transportation difﬁ-
culties often prevented women from delivering at health facilities. The
project covered 10 Woredas (districts) and 100 rural Kebeles (wards)
in theWest Gojjam and North Gondar Administrative Zones of Amhara.
The youth mentors went from house to house in their communities,
registering pregnant women, noting their expected delivery dates, and
educating them, their family members, and community leaders about
postpartum hemorrhage and misoprostol. Pregnant women were
instructed to call the mentors and health extension workers when
labor began. Thementors were responsible for bringing themisoprostol
to the birth, when either they or the health extension worker adminis-
tered it a few minutes after delivery.
The premise on which the Ethiopia model hinges—that lay youth
mentors could help to reach women who might not otherwise be
served—was proven true. The project successfully provided information
about misoprostol to about half of the 5119 pregnant women living in
the project areas. Additionally, there were no serious adverse events
reported among women given misoprostol. However, misoprostol was
administered to only 351 of the 1251 women who delivered during
the 5-month project period because logistical challenges (long
distances, road washouts, and unpredictable deliveries) prevented
mentors and health extension workers from reaching women in labor
in a timely manner. Given that no uterotonics were previously available
for home births in the project area, this represented a signiﬁcant
increase in uterotonic coverage.Nigeria
tribution: CHEWs and TBAs educate
omen about misoprostol and facility
men receive misoprostol from
-month prenatal care visit
Hybridmodel: TBAs bring the misoprostol to the
women as part of clean delivery kits, either
before or during the delivery; drug keepers
stock and dispense the pills to pregnant women,
their relatives (e.g. husbands), and TBAs
f birth (used at home or taken to In advance of birth and at home birth
th Service Created new structures, including drug
keepers, Community Oriented Resource
Persons, and newly-hired TBAs
uterotonic coverage of home births;
cility delivery
Increase in uterotonic coverage of home births
ources for expansion of model to
areas;
out misuse
Community structures difﬁcult to sustain;
Difﬁculty ensuring consistent supply of
misoprostol;
Concern about misuse
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of concerns about the reliance on non-health workers to distribute
misoprostol and its potential use for inducing abortion. Since the project
ended, the EthiopianGovernment hasmade amajor policy shift to focus
on promoting institutional delivery; this will have a signiﬁcant impact
on future efforts to scale up community-based misoprostol distribution
given the perception that the two efforts are incompatible.
3.3. Ghana: Advance distribution through the health system’s prenatal care
program
In 2008, the Earth Institute at Columbia University (New York, NY,
USA), in partnership with the University of Illinois (IL, USA), launched
a pilot project entitled the “Continuum of Care for the Prevention of
Postpartum Hemorrhage,” which included advance distribution of
misoprostol to pregnant women. The project was implemented in the
Bonsaaso Millennium Village, located in Ghana’s Amansie West district
in Ashanti Region. The project operated through seven primary health
clinics serving a population of 30 000. In theGhanamodel, health exten-
sion workers visited women in the community to educate them about
prenatal care and safe delivery measures, including misoprostol.
Women were encouraged to seek prenatal care, including during the
third trimester when they could receive misoprostol (96% of pregnant
women in Ghana attend at least one prenatal clinic [17]). During the
7-month prenatal visit, midwives educated women about safe delivery,
including both the recommendation for facility delivery and how to use
misoprostol for postpartum hemorrhage, and provided them with a
dose of misoprostol to take home. Women who could not make it to a
facility for delivery were encouraged to summon a health extension
worker or traditional birth attendant to assist with home birth.
Misoprostol was distributed to 654 women during the ﬁrst phase of
the project, 529 (80.9%) of whom delivered at a facility and did not use
the pills they had been given in advance. The misoprostol was used at
home by 96 (14.7%) women, all but one of whom used it correctly; no
maternal death was recorded during implementation of the project [20].
The Ghana model’s three key elements—integration with the health
system’s continuum of care; use of community health workers and
traditional birth attendants for outreach, education, and delivery
assistance; and advance distribution of tablets—were instrumental to
its success in helping women to have safe births, whether in a facility
or at home. In particular, the evaluation found that community stake-
holders and policy makers had a high level of acceptance of the model;
they believed that distributing misoprostol to women in advance
through the healthcare system was an effective strategy for increasing
uterotonic coverage at birth, both because it provided uterotonic cover-
age for home births when none had been previously available and also
because it encouraged women to present at facilities for delivery. In
2014, a follow-on grant was approved to expand the reach of the pilot
project to the entire Amansie West district and replicate it in three
districts in the Savanna Accelerated Development Authority zone of
Northern Ghana. Ghana is now well poised to expand community-
based misoprostol services to women in other rural communities,
where access to prenatal care is high but facility delivery is still limited.
3.4. Nigeria: Hybrid model of community distribution for use during home
delivery
In 2009, Ahmadu Bello University in Zaria, and Venture Strategies
Innovations conducted a pilot study in Zaria, Nigeria, using a hybrid
model of distribution in which women could access misoprostol
through community agents in advance of delivery or at the time of a
home birth. The pilot study demonstrated that misoprostol can safely
and effectively be used by women delivering at home and that its use
can reduce postpartum hemorrhage during home deliveries—the pilot
increased uterotonic coverage at birth, resulting in a 50% reduction in
postpartum hemorrhage [21].In 2010, the MacArthur Foundation made a strategic grant to
Ahmadu Bello University to expand this model in 11 communities in
Kaduna State and two in Sokoto State, anticipating that a successful rep-
lication in other states would encourage scale-up of the intervention
throughout the country. Themodel employed the same two approaches
that had been used in Zaria: community engagement designed to gain
support and create demand, and community-based distribution of mi-
soprostol directly to women in advance and at delivery. The project
employed three cadres of community-based workers: traditional birth
attendants to counsel pregnantwomen and bring them themisoprostol
either before they delivered or during the delivery (in the form of clean
delivery kits containing misoprostol); community oriented resource
persons to counsel and support pregnant women, and help to raise
community awareness of the importance of misoprostol in saving a
woman’s life; and drug keepers, nominated bymembers of the commu-
nity, to stock and dispense the misoprostol to pregnant women,
members of their families, and traditional birth attendants.
Like the Zaria pilot, the Kaduna and Sokoto projects were perceived
by key stakeholders to have been effective in preventing postpartum
hemorrhage. However, the model has yet to be scaled up nationally.
This is partly because it created new structures (community oriented
resource persons and drug keepers) rather than integrating the
approachwithin existing community structures (the healthcare system,
social marketing programs, Ward Development Committees). As a
result, it is difﬁcult to establish and sustain in new areas. The biggest
challenge the Nigeria model faces for national scale-up is a national pol-
icy that limits the distribution of misoprostol to trained community
agents; as long as the Federal Ministry of Health rules that community
health extension workers and traditional birth attendants are not
considered “trained community agents,” the Zariamodelwill be difﬁcult
to replicate because it revolves around the distribution of misoprostol
by these community-based workers. Nevertheless, the model has
served as inspiration for other initiatives, the most notable being the
USAID Targeted States High Impact Project, which has adapted several
aspects of themodel in its efforts to take community-based distribution
of misoprostol to scale in Bauchi and Sokoto States.
3.5. Common challenges for scale-up
Scaling up interventions from small pilot projects and integrating
them into existing healthcare systems is difﬁcult for any government,
no matter how successful the pilot [22]. Pilot projects that incorporate
recognized elements of successful scale-up from the outset—such as
those that address a compelling need, are evidence-based, are endorsed
by credible sources, are observable so that potential users can see the re-
sults in practice, and are compatible with the system’s established
values, norms, and facilities—stand the best chance of success [23]. Al-
though all three models successfully addressed key elements necessary
for scale-up—they legitimizedmisoprostol by generating evidence, built
constituencies and gained political and community support, and
modiﬁed organizational structures, successfully shifting responsibilities
of health workers to increase access—none of the pilot projects has
achieved full scale. The challenges inherent in scaling up misoprostol
for prevention of postpartum hemorrhage are not unique to these pro-
jects; experience from around the globe suggests that efforts to scale up
misoprostol for postpartum hemorrhage will require time, champions,
and sustained resources [24,25].
Each country faces unique challenges but all encountered three
obstacles in common: concern that community-level distribution of
misoprostol would undermine efforts to increase facility deliveries; re-
luctance of healthcare providers and policy makers to give misoprostol
to women in advance of their delivery and to trust them to use it
correctly, including concerns about possible “misuse” (for induced
abortion) of misoprostol by women and lay workers; and difﬁculties
ensuring a consistent supply of misoprostol. Those that were most
successful at increasing uterotonic coverage at birth incorporated the
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sustainability and will be helpful for scale-up.4. Discussion
The collective experience of these threemodels of community-based
distribution of misoprostol, combined with evidence from projects
in other countries, provides important lessons learned and recommen-
dations for these and other countries as they develop and scale up
approaches to prevent postpartum hemorrhage.
Misoprostol can save lives in countrieswherewomen still deliver
at home
Ensuring access to misoprostol at the community level, particularly
in countries where a substantial proportion of women deliver at
home, can greatly assist governments in meeting their goals to reduce
maternal mortality while they continue their efforts to strengthen
healthcare facilities and increase facility deliveries [4–8]. But in some
places (such as in the project area in Ethiopia), the distribution of
misoprostol at the community level has been curtailed because of the
perception that helping women to safely deliver at home undermines
the government’s goal of increasing institutional deliveries. This
belief—that community-based distribution competes with or even
undermines women’s use of health facilities—is not supported by the
evidence [26–29]; in the Ghana project, working in the communities
and positioning misoprostol as part of a continuum of care appears to
have increased women’s use of facilities (from 30% to 69% over the
course of the project [unpublished data]).
Advance distribution is the most successful approach, but
mistrust is stalling progress
The global evidence in support of advanced distribution ofmisopros-
tol to women to prevent postpartum hemorrhage is clear and incontro-
vertible; there is no further need for pilot studies to demonstrate the
feasibility or effectiveness of this approach [7,30,31]. Nonetheless, the
present evaluation found that a pervasive lack of trust in women’s
capabilities to use misoprostol correctly and the widely held belief that
women might “misuse” the pills (for abortion) persist, despite a lack of
evidence. Additionally, fears that providers (doctors, midwives, and tra-
ditional birth attendants) will inappropriately use misoprostol for labor
induction and/or abortion are behind the numerous restrictions regard-
ing who can deliver the drug to women. These restrictions pose the
biggest obstacle for distribution models that depend on lay workers,
who are often those most able to reach women in very rural areas.
Product issues can hinder scale-up
In all three countries, product issues that will have to be resolved
as models scale up include packaging a single-dose misoprostol
product for advanced provision to prevent postpartum hemorrhage
(already available in 6 countries, including Nigeria), challenges
inherent in assuring a steady supply of the drug at all levels of the
delivery system, and the variable quality of available misoprostol
products [32].
Distribution through existing systems hasmore scale-up potential
In themodels evaluated, themost sustainable and scalable programs
embraced existing structures and access points to women. The Ghana
program capitalized on the high attendance rate for prenatal care, dis-
tributing misoprostol to women who attended in their seventh month
of pregnancy. Safe birth kits are another prenatal service that is being
used in some places as a distribution mechanism for misoprostol.
Additionally, task shifting to community health workers, traditional
birth attendants, and other lay workers was successfully used in all
three countries to expand the reach to more rural areas. Although not
utilized in any of these three projects, all three countries have strong
pharmacy and medicine vendor networks, as well as established social
marketing programs. These private-sector resources are well situated
to partner with the public sector to increase access to misoprostol at
the community level.5. Conclusion
Providing misoprostol at the community level—although not a
replacement for facility-based efforts to promote safe delivery and
prevent postpartum hemorrhage—can help to save lives among women
in rural areas who do not yet have access to these services. Misoprostol
has the potential to be a “game changer” when it comes to maternal
health, but making good on its promise to reduce postpartum hemor-
rhage among women who deliver at home will require moving away
from the “provider” frame and addressing pervasive biases regarding
women’s capability to help themselves. These and other projects have
shown that it can be done. The challenge now is to do it on the national
scale and ensure that all women who could beneﬁt from this simple yet
effective technology have access to it.
A drug as important as miso should be accessible by all and not just in
speciﬁc communities.Wewant scale up nowbecause the drug saves lives.
Queen Mother, Amansie West District, GhanaConﬂict of interest
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